Lexicon Pharmaceuticals Inc (LXRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lexicon Pharmaceuticals Inc (LXRX) has a cash flow conversion efficiency ratio of -0.073x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.73 Million) by net assets ($202.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Lexicon Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Lexicon Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Lexicon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lexicon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lexicon Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore LXRX cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Hongtu Technology Holdings Co Ltd
SHE:002101
|
0.023x |
|
Guangdong Guanhao High-Tech Co Ltd
SHG:600433
|
-0.001x |
|
Mahindra Lifespace Developers Limited
NSE:MAHLIFE
|
-0.068x |
|
Summit
TA:SMT
|
0.016x |
|
Hubei Tech Semiconductors Co
SHE:300046
|
0.008x |
|
Jiangsu Zhenjiang New Energy Equipment Co Ltd Class A
SHG:603507
|
-0.026x |
|
Dongfeng Electronic Technology Co Ltd
SHG:600081
|
0.063x |
|
Dazzle Fashion Co Ltd
SHG:603587
|
0.031x |
Annual Cash Flow Conversion Efficiency for Lexicon Pharmaceuticals Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Lexicon Pharmaceuticals Inc from 1999 to 2025. View Lexicon Pharmaceuticals Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $107.54 Million | $-67.85 Million | -0.631x | +48.49% |
| 2024-12-31 | $145.95 Million | $-178.78 Million | -1.225x | +29.55% |
| 2023-12-31 | $93.11 Million | $-161.90 Million | -1.739x | -129.21% |
| 2022-12-31 | $117.12 Million | $-88.85 Million | -0.759x | +0.97% |
| 2021-12-31 | $113.59 Million | $-87.02 Million | -0.766x | +16.22% |
| 2020-12-31 | $156.37 Million | $-142.97 Million | -0.914x | -194.08% |
| 2019-12-31 | $117.10 Million | $113.81 Million | 0.972x | -82.73% |
| 2018-12-31 | $-26.41 Million | $-148.61 Million | 5.628x | +258.17% |
| 2017-12-31 | $52.10 Million | $-185.39 Million | -3.558x | -218.90% |
| 2016-12-31 | $157.40 Million | $-175.63 Million | -1.116x | -272.62% |
| 2015-12-31 | $285.85 Million | $184.78 Million | 0.646x | +342.78% |
| 2014-12-31 | $284.02 Million | $-75.62 Million | -0.266x | +50.26% |
| 2013-12-31 | $170.16 Million | $-91.08 Million | -0.535x | -51.11% |
| 2012-12-31 | $266.68 Million | $-94.46 Million | -0.354x | -19.86% |
| 2011-12-31 | $297.57 Million | $-87.94 Million | -0.296x | +11.37% |
| 2010-12-31 | $247.02 Million | $-82.37 Million | -0.333x | +38.76% |
| 2009-12-31 | $163.50 Million | $-89.02 Million | -0.544x | -11.53% |
| 2008-12-31 | $195.83 Million | $-95.60 Million | -0.488x | -88.23% |
| 2007-12-31 | $286.57 Million | $-74.32 Million | -0.259x | +61.03% |
| 2006-12-31 | $85.50 Million | $-56.91 Million | -0.666x | -343.62% |
| 2005-12-31 | $85.80 Million | $23.44 Million | 0.273x | +178.62% |
| 2004-12-31 | $121.59 Million | $-42.26 Million | -0.348x | -648.61% |
| 2003-12-31 | $166.22 Million | $-7.72 Million | -0.046x | +72.61% |
| 2002-12-31 | $169.90 Million | $-28.79 Million | -0.169x | -105.70% |
| 2001-12-31 | $218.37 Million | $-17.99 Million | -0.082x | -1039.20% |
| 2000-12-31 | $207.63 Million | $-1.50 Million | -0.007x | +99.38% |
| 1999-12-31 | $8.20 Million | $-9.60 Million | -1.171x | -- |
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercialize… Read more